<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1331">
  <stage>Registered</stage>
  <submitdate>1/06/2006</submitdate>
  <approvaldate>28/06/2006</approvaldate>
  <actrnumber>ACTRN12606000260527</actrnumber>
  <trial_identification>
    <studytitle>Peppermint oil for flexible sigmoidoscopy pre-medication</studytitle>
    <scientifictitle>Does pre-medication with peppermint oil improve adenoma detection rate in a flexible sigmoidoscopy based colorectal cancer screening study?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal cancer screening</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All attenders at a flexible sigmoidoscopy based colorectal cancer screening group are invited to participate in this substudy.                                                                                                    Participants are randomly allocated to receive a peppermint oil capsule taken orally at least 30 minutes prior to undergoing sigmoidoscopy.                                                                           Additionally, the same participants are randomly allocated to recieve one (standard care) or two phosphate enemas per rectum as bowel preparation also at least 30 minutes prior toprior to sigmoidoscopy.                                                                                                                                                                                                                                                                 Both interventions are single administrations only on the day of sigmoidoscopy.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adenoma detection rate at sigmoidoscopy. Polyp detection is determined immediately at sigmoidoscopy.Pathology reports 5-7 days later are obtained to determine if the polyp was adenomatous.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Insertion depth</outcome>
      <timepoint>Time point: at time of sigmoidoscopy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain score</outcome>
      <timepoint>Time point: immediately following sigmoidoscopy </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Faecal clearance score</outcome>
      <timepoint>Time point: assessed by independent blinded reviewer based on photo taken at time of sigmoidoscopy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All participants of a flexible sigmoidoscopy based colorectal cancer screening program.</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>If allergy to peppermint oil, severe symptomatic gastro-oesophageal reflux disease, use of any analgesics on the day of the sigmoidoscopy prior to the procedure.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Use of numbered containers</concealment>
    <sequence>Simple randomisation by selection of folded, numbered pieces of paper from a container</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>2/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Charlie Viiala</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Fremantle Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor John Olynyk</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The screening program with flexible sigmoidoscopy has been operating for 10 years. Up to 40% of participants do not reattend, largely due to concerns over pain and discomfort and our data indicates that high pain scores and poor bowel cleansing are associated with reduced detection of colonic adenomas. We aim to assess the efficacy of peppermint oil in improving adenoma detection by reducing pain. Additionally, the efficacy of two enemas rather than the standard one enema in improving bowel cleansing and adenoma detectionwill be assessed. Participants, the procedualist, staff interviewing subjects after sigmoidoscopy and the data analyst are blinded to the nature of the interventions. Study will be unblinded following adequate recruitment</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Fremantle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/12/2005</ethicapprovaldate>
      <hrec>05/447</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Charlie Viiala</name>
      <address>Endoscopy Unit
Fremantle Hospital
Alma St
Fremantle
WA 6160</address>
      <phone>(08) 9431 2300</phone>
      <fax>(08) 9431 2340</fax>
      <email>charliev@iinet.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Charlie Viiala</name>
      <address>Endoscopy Unit
Fremantle Hospital
Alma St
Fremantle
WA 6160</address>
      <phone>(08) 9431 2300</phone>
      <fax>(08) 9431 2340</fax>
      <email>charliev@iinet.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>